SIR1-365 for COVID-19: real-time analysis

Download Image

Post

c19early.org

SIR1-365 for COVID-19

1 study with 42 patients

No significant improvements are seen in meta-analysis to date.

COVID-19 SIR1-365 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−88%

RCTs (1)−88%

Late (1)−88%

00.511.5+

← SIR1-365
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

SIR1-365 is an oral small-molecule RIPK1 kinase inhibitor with anti-inflammatory and immunomodulatory activity.


Nov 27 2021	Qu et al., NCT04622332	A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19
Nov 27 2021	88% worse recovery (p=0.44). Pilot RCT 42 hospitalized COVID-19 patients showing no significant differences with SIR1-365 treatment. foo